MedTrace Logo

Post Market Surveillance to Observe Safety of Prevenar13™ in Adults

NCT01834222 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 659

Last updated 2017-04-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess safety profile of Prevenar 13™ when used among Korean adults in the routine clinical setting, as required for any new drug approved by Korea Food and Drug Administration (KFDA).

Conditions

  • Pneumococcal Disease

Interventions

BIOLOGICAL

Non-intervention

Non-intervention

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01834222 on ClinicalTrials.gov